Nevro Corp. (NVRO)
NYSE: NVRO · Real-Time Price · USD
3.720
-0.330 (-8.15%)
Dec 27, 2024, 11:00 PM EST - Market closed
Nevro Revenue
Nevro had revenue of $96.91M in the quarter ending September 30, 2024, a decrease of -6.69%. This brings the company's revenue in the last twelve months to $419.15M, down -0.87% year-over-year. In the year 2023, Nevro had annual revenue of $425.17M with 4.63% growth.
Revenue (ttm)
$419.15M
Revenue Growth
-0.87%
P/S Ratio
0.33
Revenue / Employee
$344,976
Employees
1,215
Market Cap
139.39M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 425.17M | 18.81M | 4.63% |
| Dec 31, 2022 | 406.37M | 19.46M | 5.03% |
| Dec 31, 2021 | 386.91M | 24.86M | 6.87% |
| Dec 31, 2020 | 362.05M | -28.21M | -7.23% |
| Dec 31, 2019 | 390.26M | 2.97M | 0.77% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 393.90B |
| Johnson & Johnson | 87.70B |
| Merck & Co. | 63.17B |
| AbbVie | 55.53B |
| AstraZeneca | 51.21B |
| Novartis AG | 49.94B |
| Thermo Fisher Scientific | 42.37B |
| Abbott Laboratories | 41.22B |
NVRO News
- 11 days ago - Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08 - PRNewsWire
- 26 days ago - Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos - Benzinga
- 5 weeks ago - New Study Demonstrates Multiple Advantages of Nevro1™, the Novel SI Joint Fusion System by Nevro, in Comparison to Posterolateral and Lateral Approaches - PRNewsWire
- 6 weeks ago - Nevro's HFX iQ™ Spinal Cord Stimulation with AI Technology Receives CE Mark Certification in Europe, Increasing Product Expansion Globally - PRNewsWire
- 6 weeks ago - Nevro Corp. (NVRO) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Nevro Reports Third-Quarter 2024 Financial Results - PRNewsWire
- 2 months ago - New Data Demonstrates Long-Term Improvements in Pain Intensity with Nevro's High-Frequency Spinal Cord Stimulation Therapy - PRNewsWire
- 2 months ago - Nevro to Report Third-Quarter 2024 Financial Results and Host Earnings Conference Call on November 11, 2024 - PRNewsWire